Subsequently, we investigated the effects of two different GITR agonists in combination with TGF-β inhibition in syngeneic glioma models, both in vitro and in vivo, laying the groundwork for further exploration of this novel dual immunotherapeutic strategy in glioblastoma. Here, TGFB1 is linked to central nervous system cancer.